SG11202109738QA - Recombinant ccn domain proteins and fusion proteins - Google Patents
Recombinant ccn domain proteins and fusion proteinsInfo
- Publication number
- SG11202109738QA SG11202109738QA SG11202109738QA SG11202109738QA SG 11202109738Q A SG11202109738Q A SG 11202109738QA SG 11202109738Q A SG11202109738Q A SG 11202109738QA SG 11202109738Q A SG11202109738Q A SG 11202109738QA
- Authority
- SG
- Singapore
- Prior art keywords
- seq
- protein
- sequence
- amino acid
- fusion protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19163970.7A EP3711772A1 (en) | 2019-03-20 | 2019-03-20 | Recombinant proteins and fusion proteins |
| PCT/EP2020/057773 WO2020188081A1 (en) | 2019-03-20 | 2020-03-20 | Recombinant ccn domain proteins and fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109738QA true SG11202109738QA (en) | 2021-10-28 |
Family
ID=66102364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109738Q SG11202109738QA (en) | 2019-03-20 | 2020-03-20 | Recombinant ccn domain proteins and fusion proteins |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12606602B2 (https=) |
| EP (2) | EP3711772A1 (https=) |
| JP (1) | JP7600135B2 (https=) |
| KR (1) | KR20210142681A (https=) |
| CN (1) | CN113747912B (https=) |
| AU (1) | AU2020243073B2 (https=) |
| BR (1) | BR112021017147A2 (https=) |
| CA (1) | CA3133740A1 (https=) |
| IL (1) | IL285930B2 (https=) |
| MX (1) | MX2021011407A (https=) |
| SG (1) | SG11202109738QA (https=) |
| WO (1) | WO2020188081A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023552810A (ja) * | 2020-12-08 | 2023-12-19 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 抗ｅｇｆｒキメラ抗原受容体 |
| GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
| GB202400055D0 (en) * | 2024-01-03 | 2024-02-14 | Tribune Therapeutics Ab | Use of ccn domain-containing proteins for the treatment of disease |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
| GB8909916D0 (en) | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1999047556A2 (en) * | 1998-03-19 | 1999-09-23 | Trustees Of Tufts College | Novel heparin-induced ccn-like molecules and uses therefor |
| EP1326980B1 (en) * | 2000-10-16 | 2008-03-19 | Genentech, Inc. | Methods of treatment using wisp polypeptides |
| CN1835763B (zh) | 2003-06-20 | 2011-04-20 | 妙甯公司 | Ccn1组合物和方法 |
| FR2858234B1 (fr) | 2003-08-01 | 2007-09-14 | Centre Nat Rech Scient | Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers |
| EP1771467A2 (en) | 2004-07-26 | 2007-04-11 | Asterion Limited | Linkers |
| ATE506961T1 (de) * | 2005-01-10 | 2011-05-15 | Univ Rosalind Franklin Medicine & Science | Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen |
| CN101146826A (zh) | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| EP2015781A4 (en) * | 2005-09-12 | 2009-12-23 | Univ Johns Hopkins | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US20080207489A1 (en) | 2007-02-21 | 2008-08-28 | John Castellot | Use of CCN5 for treatment of smooth muscle proliferation disorders |
| WO2009086132A2 (en) | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| DK3061817T3 (en) * | 2009-04-30 | 2019-03-04 | Kao Corp | Alkaline protease variants |
| TW201102086A (en) | 2009-06-04 | 2011-01-16 | Hoffmann La Roche | Antibodies against human CCN1 and uses thereof |
| JP5820378B2 (ja) * | 2009-09-09 | 2015-11-24 | ファーマイン コーポレーションＰｈａｒｍａｉｎ Ｃｏｒｐｏｒａｔｉｏｎ | 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法 |
| MX340971B (es) | 2009-11-23 | 2016-08-02 | Amgen Inc * | Fragmento cristalizable (fc) de anticuerpo monomerico. |
| KR101187814B1 (ko) | 2010-03-22 | 2012-10-08 | 광주과학기술원 | 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법 |
| JP5939584B2 (ja) | 2010-04-02 | 2016-06-22 | ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス | 治療用ｃｃｎ３ペプチドおよびそれらの類似体 |
| US9114112B2 (en) * | 2010-04-02 | 2015-08-25 | Rosalind Franklin University Of Medicine And Science | CCN3 and CCN3 peptides and analogs thereof for therapeutic uses |
| PT2621515T (pt) * | 2010-09-28 | 2017-07-12 | Aegerion Pharmaceuticals Inc | Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada |
| ES2623912T3 (es) | 2010-12-23 | 2017-07-12 | Janssen Biotech, Inc. | Mutantes FC de anticuerpo activo resistente a proteasa |
| WO2014008582A1 (en) | 2012-07-11 | 2014-01-16 | The University Of Western Ontario | Method of treating wounds with penostin and/or ccn2 |
| US20140271641A1 (en) | 2013-03-14 | 2014-09-18 | University Of Guelph | Thrombospondin-1 polypeptides and methods of using same |
| GB201316592D0 (en) | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| AU2016228806B2 (en) | 2015-03-12 | 2020-10-22 | Medimmune, Llc | Method of purifying albumin-fusion proteins |
| JP2018517708A (ja) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
| GB201512733D0 (en) | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
| CN105396136B (zh) * | 2015-11-23 | 2018-10-30 | 上海交通大学医学院附属第九人民医院 | CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用 |
| EP3192806A1 (en) | 2016-01-13 | 2017-07-19 | Affiris AG | Alpha chain of the high-affinity ige receptor (fceria) |
| CA3011887C (en) | 2016-03-14 | 2024-10-29 | Universitetet I Oslo | Genetically transformed immunoglobulins with altered FCRN binding |
| US10028906B2 (en) | 2016-03-22 | 2018-07-24 | Rosalind Franklin University Of Medicine And Science | Method and kit for treating a solid tumor and associated desmoplasia |
| US11795202B2 (en) | 2016-08-04 | 2023-10-24 | Stichting Vumc | Fusion polypeptide comprising a foreign antigen and self antigen |
| US20180127478A1 (en) | 2016-09-16 | 2018-05-10 | Wei-Chiang Shen | SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY |
| KR20180099537A (ko) * | 2017-02-28 | 2018-09-05 | 주식회사 파이안바이오테크놀로지 | 근섬유모세포의 병리적 활성이 초래하는 섬유증식성 질병 치료제 |
| KR102008407B1 (ko) | 2017-09-05 | 2019-08-08 | 한국생명공학연구원 | 코돈 최적화된 il-21 및 이의 용도 |
| WO2019071007A1 (en) | 2017-10-05 | 2019-04-11 | New York Genome Center, Inc. | METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMETTISM |
-
2019
- 2019-03-20 EP EP19163970.7A patent/EP3711772A1/en not_active Withdrawn
-
2020
- 2020-03-20 AU AU2020243073A patent/AU2020243073B2/en active Active
- 2020-03-20 BR BR112021017147A patent/BR112021017147A2/pt unknown
- 2020-03-20 IL IL285930A patent/IL285930B2/en unknown
- 2020-03-20 US US17/440,576 patent/US12606602B2/en active Active
- 2020-03-20 WO PCT/EP2020/057773 patent/WO2020188081A1/en not_active Ceased
- 2020-03-20 CN CN202080023396.5A patent/CN113747912B/zh active Active
- 2020-03-20 CA CA3133740A patent/CA3133740A1/en active Pending
- 2020-03-20 KR KR1020217033515A patent/KR20210142681A/ko not_active Ceased
- 2020-03-20 EP EP20711209.5A patent/EP3941507A1/en active Pending
- 2020-03-20 JP JP2021556442A patent/JP7600135B2/ja active Active
- 2020-03-20 SG SG11202109738Q patent/SG11202109738QA/en unknown
- 2020-03-20 MX MX2021011407A patent/MX2021011407A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL285930B1 (en) | 2024-09-01 |
| CN113747912A (zh) | 2021-12-03 |
| EP3941507A1 (en) | 2022-01-26 |
| BR112021017147A2 (pt) | 2021-11-09 |
| JP7600135B2 (ja) | 2024-12-16 |
| CA3133740A1 (en) | 2020-09-24 |
| AU2020243073B2 (en) | 2025-06-05 |
| US20220144903A1 (en) | 2022-05-12 |
| EP3711772A1 (en) | 2020-09-23 |
| IL285930B2 (en) | 2025-01-01 |
| US12606602B2 (en) | 2026-04-21 |
| MX2021011407A (es) | 2022-01-24 |
| IL285930A (en) | 2021-10-31 |
| KR20210142681A (ko) | 2021-11-25 |
| AU2020243073A1 (en) | 2021-11-11 |
| JP2022525661A (ja) | 2022-05-18 |
| WO2020188081A1 (en) | 2020-09-24 |
| CN113747912B (zh) | 2025-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101993714B1 (ko) | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 | |
| TWI513705B (zh) | 纖維母細胞生長因子２１蛋白質 | |
| Alexander et al. | Characterization and modelling of the hydrophobic domain of a sunflower oleosin | |
| JP2017528419A (ja) | Ｍｉｃ−１融合タンパク質及びその使用 | |
| KR20190129896A (ko) | Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도 | |
| US12606602B2 (en) | Recombinant CCN domain proteins and fusion proteins | |
| CN114591415B (zh) | Glp-1/gcg双受体激动剂多肽及其融合蛋白 | |
| KR102682612B1 (ko) | N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도 | |
| CA3000697A1 (en) | Treatment of bile acid disorders | |
| US20170334971A1 (en) | Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof | |
| US20070111944A1 (en) | Purification of vascular endothelial growth factor-B | |
| US20040137588A1 (en) | Purification of vascular endothelial growth factor-b | |
| RU2825102C2 (ru) | Рекомбинантные белки с доменами ccn и слитые белки | |
| US20220348623A1 (en) | Stabilized proteolytically activated growth differentiation factor 11 | |
| KR20240126875A (ko) | Glp-1과 gdf15의 융합 단백질 및 이의 용도 | |
| KR20220006013A (ko) | 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도 | |
| KR20180003677A (ko) | 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 | |
| KR20160013730A (ko) | 세포투과성이 우수한 ｔａｔ－ａ２０ 융합단백질의 제조방법 및 이의 용도 | |
| CN108424459A (zh) | 人血清白蛋白与人突变型肝细胞生长因子的融合蛋白及其制备方法和应用 | |
| RU2021130848A (ru) | СЛИТЫЙ ПОЛИПЕПТИД, ВКЛЮЧАЮЩИЙ Fc ОБЛАСТЬ ИММУНОГЛОБУЛИНА И GDF15 | |
| WO2015161832A1 (zh) | 长效重组人干扰素α2b-Fc融合蛋白 |